Jnana Therapeutics launched with a $50 million Series A financing. Seed funders Polaris Partners and Avalon Ventures were joined in the round by Versant Ventures, AbbVie Ventures and Pfizer R&D Innovate.
Merck & Co.’s Keytruda came up short in a pivotal study as a second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Belgium-based reMYND’s pre-clinical diabetes therapy ReS39 will get a significant boost after the company entered a licensing agreement with noted European diabetes company Novo Nordisk.
Teva Pharmaceutical announced a comprehensive restructuring plan that includes the elimination of 25 percent of the company’s global workforce.
Impressive top-line results were reported from a pivotal Phase II study for the PD-1 inhibitor cemiplimab.
Daiichi Sankyo Europe GmbH informed Nektar Therapeutics that it was terminating a collaboration and licensing deal, which becomes effective Feb. 4, 2018. All rights and licenses that Daiichi acquired in the deal will revert to Nektar.
Johnson & Johnson topped the Bioethics International “Good Pharma Scorecard” for the second year in a row.
Allergan is buying Repros Therapeutics for $0.67 per share. The deal is expected to close in the first quarter of 2018.
Privately held Dart NeuroScience and its quest to develop therapies intended to improve cognitive vitality will close its doors on Feb. 9, 2018, due to poor progress on the San Diego-based company’s therapeutic goals and little return on hundreds of millions of dollars in research and development.
At the American Society of Hematology meeting, Genentech revealed long-term data showing the drug maintains its efficacy over an extended period of time.
Summit, NJ-based Celgene and Cambridge, Mass.-based bluebird bio released updated data from an ongoing Phase I clinical trial of bb2121 at the American Society of Hematology (ASH) Annual Meeting in Atlanta.
Scientists have for the first time fixed a protein defect that causes Huntington’s disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease.
With one year of operations now under its belt since the grand opening, pharma giant GlaxoSmithKline has a bold future planned for its research and development facility in Maryland.
Denali Therapeutics – launched in May 2015 by three former Genentech researchers – went public, raising $250 million with shares priced at $18.
San Diego’s Halozyme Therapeutics tied up a licensing agreement with Connecticut-based Alexion Pharmaceuticals that could net the company $680 million.
Philadelphia-based Spark Therapeutics, with its partner Pfizer, published interim data from its Phase I/II clinical trial of a gene therapy for hemophilia B in The New England Journal of Medicine.
Cambridge Biotech Obsidian Launches With $49.5M Investment From Google, Takeda, Vertex, Amgen and Others
Obsidian Therapeutics officially launched with the completion of a Series A financing worth $49.5 million. Obsidian is focusing on immuno-oncology, and includes regulated cytokine cassettes to be used with CAR-T products.
Depomed Inc. is looking to relocate its headquarters from the Bay Area after inking a deal with Collegium Pharmaceutical Inc.
J&J’s Janssen Biotech entered into a collaboration deal with Idorsia to jointly develop and market aprocitentan for hypertension and any derivative compounds.
Shares of Ultragenyx sharply climbed after the company announced positive results from its Phase III study of burosumab in adults with X-linked hypophosphatemia (XLH).